James J. Burns & Company LLC Buys 142,743 Shares of Henry Schein, Inc. $HSIC

James J. Burns & Company LLC increased its position in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 1,293.7% during the first quarter, Holdings Channel reports. The institutional investor owned 153,777 shares of the company’s stock after purchasing an additional 142,743 shares during the quarter. Henry Schein comprises 1.5% of James J. Burns & Company LLC’s holdings, making the stock its 18th biggest position. James J. Burns & Company LLC’s holdings in Henry Schein were worth $11,333,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in HSIC. CYBER HORNET ETFs LLC bought a new stake in shares of Henry Schein in the 2nd quarter worth approximately $25,000. MUFG Securities EMEA plc bought a new stake in shares of Henry Schein during the second quarter valued at approximately $27,000. Flagship Harbor Advisors LLC acquired a new position in shares of Henry Schein in the fourth quarter valued at $30,000. Federated Hermes Inc. acquired a new position in shares of Henry Schein in the fourth quarter valued at $32,000. Finally, Los Angeles Capital Management LLC bought a new position in Henry Schein in the fourth quarter worth $37,000. 96.62% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, Director William K. Daniel acquired 10,000 shares of the firm’s stock in a transaction on Monday, May 11th. The shares were purchased at an average price of $69.19 per share, with a total value of $691,900.00. Following the acquisition, the director directly owned 20,000 shares in the company, valued at $1,383,800. The trade was a 100.00% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. 0.89% of the stock is currently owned by corporate insiders.

Henry Schein Trading Down 1.6%

Shares of Henry Schein stock opened at $78.67 on Tuesday. The company has a quick ratio of 0.75, a current ratio of 1.36 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $8.96 billion, a P/E ratio of 23.77, a price-to-earnings-growth ratio of 1.54 and a beta of 0.82. Henry Schein, Inc. has a 12-month low of $61.94 and a 12-month high of $89.29. The company has a 50-day simple moving average of $76.02 and a 200 day simple moving average of $76.48.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $1.32 earnings per share for the quarter, topping the consensus estimate of $1.20 by $0.12. Henry Schein had a net margin of 2.95% and a return on equity of 15.44%. The company had revenue of $3.37 billion during the quarter, compared to analyst estimates of $3.34 billion. During the same quarter last year, the business posted $1.15 earnings per share. The company’s revenue was up 6.3% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Research analysts expect that Henry Schein, Inc. will post 5.32 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on HSIC shares. Citigroup started coverage on shares of Henry Schein in a research note on Wednesday, April 15th. They set a “buy” rating and a $100.00 price target on the stock. Mizuho dropped their price objective on shares of Henry Schein from $88.00 to $82.00 and set a “neutral” rating for the company in a research note on Wednesday, May 6th. BTIG Research raised shares of Henry Schein from a “neutral” rating to a “buy” rating and set a $100.00 price objective for the company in a report on Thursday, June 11th. Morgan Stanley reiterated an “underweight” rating and set a $64.00 target price (up from $61.00) on shares of Henry Schein in a research report on Friday, April 24th. Finally, Barrington Research set a $97.00 target price on shares of Henry Schein and gave the company an “outperform” rating in a research note on Wednesday, February 25th. Seven research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $87.85.

Henry Schein Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.